

Polishing

Economic evaluation of Polisher ST membrane adsorber replacing an AEX polishing column in a mAb manufacturing process

Joris Van de Velde, Hani El-Sabbahy, Matthew Peters, Alexei Voloshin, and Himanshu Nivsarkar,
Thermo Fisher Scientific, Inc.

Introduction

With increasing molecule diversity, biologic drug manufacturers are looking for platformable manufacturing solutions. With a diversified portfolio still dominated by monoclonal antibody (mAb) therapeutic proteins, an important focus is placed on process intensification which helps in lower capital expenditure investment and overall manufacturing cost. The number of molecules in the development pipeline and time to market are key factors for success.

These trends have led to a surge in demand for single-use products and solutions. Single-use technologies (SUTs) offer reduced capital expenditure, allow faster turnaround between batches, can improve changeover time between campaigns and flexibility to deal with molecular diversity in the pipeline, and can benefit the speed to market. The ability to use reliable platform technologies across different processes and molecules further decreases the time required for process development and production of clinical material.

In the past decade, cell line development and optimized cell culture technologies have shifted the bottleneck from upstream processes (USP) towards the downstream process (DSP) operations. Titrers at commercial scale have moved from less than 2 g/L and low cell density ($<10 \times 10^6$ cell/mL) processes to titers of over 7 g/L. Now the yield of the downstream operations has become the limiting factor for the output capacity of the manufacturing plant. In order to fully utilize the increased therapeutic protein mass produced, the number of downstream unit operations needs to be reduced, and the size of individual steps must be decreased to minimize product losses. New single-use technologies such as Thermo Scientific™ Polisher ST Membrane Adsorber provide manufacturers with opportunities to intensify manufacturing operations.

Single-use AEX chromatography



Figure 1: Traditional resin-based column (left) and holder with one BC16000 capsule of Thermo Scientific™ Polisher ST Membrane Adsorber (right).

Polisher ST membrane adsorber offers a single-use chromatography solution for the downstream manufacturing space, allowing replacement of multi-use chromatography columns as shown in Figure 1.

Single-use chromatography technology offers the flexibility a multiproduct manufacturing facility requires. Several studies have demonstrated that the capital investment required for a single-use facility is lower, and these facilities offer substantial time and labor savings by eliminating cleaning and cleaning validation procedures.^{1,2}

In a multiproduct and multimodality facility, the downstream operations must keep pace with the product mass expressed by the upstream part of the process. When using existing technologies, the size of the downstream unit operations increases proportionately with the batch size and product titer.

Some of the recent technology innovations which have been tested and used in the industry include high-capacity chromatography resins with higher loadings and lower residence time. Adoption of single-use chromatographic membrane adsorbers in commercial scale downstream processes has

lagged, primarily due to capacity limitations and concerns about cost effectiveness beyond lab and pilot scales. Sensitivity of the performance of AEX ligands to the process conditions, including pH, conductivity and buffer types, has hindered their application in the development of true platform processes.

To improve the overall process economics and to allow adoption of single-use equipment at any scale, disposable chromatography solutions need to show high throughput capacities and improve the product yield. In this application note, we discuss different strategies for the AEX flow-through polishing step. A comparison is made between a traditional reusable downstream polishing AEX column, a reusable AEX membrane adsorber and an advanced single-use AEX solution like Polisher ST membrane adsorber.

Polisher ST membrane adsorber in the biopharmaceutical process

Polisher ST membrane adsorber is a synthetic, hybrid polishing solution containing two complementary AEX-functional media: a quaternary ammonium (Q) functional nonwoven and a guanidinium-functional membrane (Figure 2).

The Q-functional nonwoven provides reduction of turbidity (when present), DNA, HCP, and endotoxin, and adds to the product's total charge capacity. Since Polisher ST membrane adsorber is capable of operating in turbid conditions, it can be placed directly

after the low pH virus inactivation and neutralization step (VIN), without the need for any pre-filtration. Reusable columns and membrane adsorbers typically require to be protected by a depth filter and membrane to prevent fouling and pressure buildup after a certain number of cycles. Polisher ST membrane adsorber is designed for true single use, allowing non-reversible entrapment of particles, as a new capsule will be used for the next batch.




Figure 2: Multi-layer capsule construction of Thermo Scientific™ Polisher ST Membrane Adsorber

The novel guanidinium functional membrane reduces host cell protein impurities and provides robust viral clearance in a wide range of operating conditions, including high conductivity, low pH and polyvalent buffers. The expanded operating window of the guanidinium ligand allows more freedom in designing DSP polishing trains, offering potential for process simplification and facilitating the transition to true platform processes. The combination of the different functional layers results in a very high

charge capacity, allowing typical mAb loadings of 10 kg/m² in a flowthrough mode. In this case, the m² refers to the frontal surface area of the system and is proportional to the bed volume of the chromatography media in the device. This enables deployment of Polisher ST membrane adsorber in the downstream process at all scales, including full commercial manufacturing.

Modeling the process

In this application note we explore the potential impact of replacement of an AEX flow-through column by a reusable membrane adsorber or the single use Polisher ST membrane adsorber on the cost of monoclonal antibody therapeutic manufacturing. This work describes hypothetical scenarios. Depending on product and process conditions, the effects covered in this application note may not be realized or may not be realized to the degree shown in the scenarios.

We modeled a typical single-use large scale manufacturing facility using the commercial Biosolve Process™ software package (version 8.3) from Biopharm Services Limited. The facility and process have the following attributes:

- Reactor setup: 6 single-use bioreactors with 2000 L working volume
- mAb titer = 5 g/L
- 1 reactor is harvested and purified at a time.
- Facility output of 100 batches per year
- Downstream operations utilize single-use systems as much as possible

Table 1 lists the process parameters used for the three technologies that are being compared, a traditional column, a membrane adsorber that can be cycled 100 times and a single use AEX capsule. The column and membrane adsorber are

protected by a depth filter and membrane to prevent fouling, while Polisher ST membrane adsorber is applied immediately after VIN.

This investigation covers the key potential advantages of deploying Polisher ST membrane adsorber in the biopharmaceutical manufacturing process. A commercial manufacturing sized Polisher ST membrane adsorber BC16000 capsule was used as the standard consumable format for the models. For the membrane adsorber, a capsule with 2.5 L bed volume was used for modelling.

The theoretical recovery of Polisher ST membrane adsorber is around 99%, even if up to 50% of the membrane's protein binding capacity is used for unwanted binding of the target mAb. Experimental data has shown recoveries of at least 95% for the entire intended operating range and has confirmed values around 99% to be realistic under optimized conditions. The same recovery of 99% is assumed for the reusable membrane adsorber.

Biosolve Process is an expansive model utilizing an enormous dataset from the industry in terms of operational strategy and cost. Cost databases from the software were maximally utilized. It is not possible to account for every scenario and detail. To investigate how certain parameters affect the results, and which inputs are most critical, a sensitivity analysis was performed.

Parameters	Scenario 1	Scenario 2	Scenario 3
AEX step	AEX column	Membrane adsorber (MA)	Thermo Scientific™ Polisher ST Membrane Adsorber
Post VIN DF recovery	95%	95%	NA
Post VIN membr. rec.	98%	98%	NA
Step recovery	95%	99%	99%
Hardware	column	none	EZA holder
Consumable cost	2,380 \$/L	30,000 \$/capsule	5,500 \$/capsule
Loading	200 g/L	3 kg/L	10 kg/m ²
Target cycles / batch	1 cycle	1 cycle	1 cycle
Max # cycles	150 cycles	100 cycles	1 cycle

Table 1: Main parameters and assumptions used for the different flow-through AEX solutions.

Scenario 1: Typical mAb process with reusable AEX column

Total DSP yield: 58 %




Figure 3: Base process with traditional resin-based AEX column.

Overall yield	PMI	COGS \$/g
58%	4,842	63.66

Table 2: Yield, PMI and COGS for scenario 1.

The base scenario consists of a typical mAb process with a two-stage depth filter clarification, a protein A capture step, VIN, protective filtration steps and two polishing chromatography column steps. Figure 3 shows the overall process model and the main parameters for each process step. The AEX column has a packed resin volume of 62 L. The batch is processed in a single cycle with a load of 200 g/L. The resin is reused for 150 cycles.

More detailed information on the process sequence and cost breakdown are included in the Appendix.

The DSP yield of the scenario 1 process is 58%. The summary table 2 includes the overall yield, Cost of Goods Sold (COGS) in US dollars per gram of mAb and the process mass intensity (PMI) index. This last key performance indicator is the total mass of materials, including buffers and water, used in the process, divided by the mass output of the product of interest.^{3,4} The PMI is seen as an indicator for the environmental impact of the process. Lower PMI values are associated with a lower environmental footprint, less waste and generally also lower costs.

Scenario 2: mAb process with reusable AEX membrane adsorber

Total DSP yield: 61 %




Figure 4: mAb process with reusable AEX membrane adsorber

Overall yield	PMI	COGS \$/g
61%	4,383	60.36
(+3% compared to scenario 1)	(-9% compared to scenario 1)	(-5% compared to scenario 1)

Table 3: Yield, PMI and COGS for scenario 2.

In scenario 2, the traditional AEX column is replaced by a membrane adsorber capsule. The batch is processed with a single 2.5 L capsule. The assumption is that the membrane can be regenerated and reused for 100 batches. To prevent fouling and pressure increases, the adsorber is positioned after the VIN depth filter and membrane, as shown in Figure 4.

Table 3 summarizes the results. Due to the smaller size of the membrane and its convective flow path, the recovery of the AEX step is increased from 95% to 99%. With that, the overall DSP recovery increases from 58% to 61%.

Scenario 3: mAb process with single use Polisher ST membrane adsorber step

Total DSP yield: 65 %

										
Parameter	DF 1	DF 2	Membrane	Capture	VIN	Thermo Scientific™ Polisher ST Membrane Adsorber	CEX column	Virus filter	UF/DF	Membrane
Size	14 pc	7 pc	30"	62 L	NA	1 x BC16000	78 L	2 pc	6,8 m²	10"
Batch load	100 L/m²	200 L/m²	1000 L/m²	35 g/L (4 cycles)	NA	10 kg/m²	60 g/L (2 cycles)	5000 g/m²	NA	250 L/m²
Yield %	90	90	98	90	98	99%	95	98	98	98

Figure 5: Model process with traditional depth filters and single-use AEX step.

Overall yield	PMI	COGS \$/g
65%	4,070	55.37
(+7% compared to scenario 1)	(-16% compared to scenario 1)	(-13% compared to scenario 1)

Table 4: Yield, PMI and COGS for process with single use AEX.

Polisher ST membrane adsorber is an advanced single-use solution containing two complementary AEX-functional media: A Q-functional nonwoven and a guanidinium-functional membrane. Due to its high capacity and unique guanidinium functionality, the Polisher ST membrane adsorber offers higher mAb loading than a traditional flow-through Q resin. The high capacity and convective flow of the membrane enables downsizing of the AEX polishing unit operation, while achieving an equivalent effluent quality in terms of turbidity, DNA and HCP levels.

Scenario 3 shows the effect of deploying Polisher ST membrane adsorber in the process. The batch is still processed in one cycle and the capsules are not reused. Due to its ability to operate in moderate levels of turbidity, the depth and membrane filtration steps after Virus inactivation and neutralization (VIN) can be eliminated. The process is simplified from 12 recovery and downstream unit operations to 10.

Due to the elimination of the protective filtration steps, the overall DSP yield further increases to 65%. The cost of manufacturing is decreased by 13% compared to scenario 1 and by 8% compared to scenario 2.

Cost breakdown

The AEX polishing chromatography step is not a main cost driver of the process. In scenario 1, the most cost intensive process steps are the production bioreactor (29% of total batch cost) and the protein A capture step (16%). The AEX polishing column is responsible for 7% of the total batch cost, while Polisher ST membrane adsorber accounts for 5% in the third scenario.




Figure 6: Total cost per batch for different scenarios




Figure 7: Cost breakdown for different scenarios on per gram basis

Implementation of advanced single use technology and driving intensification reduces the cost of the model processes. Figures 6 and 7 show a cost breakdown to explain the main drivers of those changes. These graphs show the total production cost of the entire process, not just the process steps that are being investigated. The production cost per batch is relative stable across the scenarios and decreases by only 3% for scenario 3 compared to scenario 1. However, the cost per gram of mAb produced is reduced by 13%. This difference is explained by an increased recovery in the single use scenario, resulting in a higher overall mAb output per batch. This yield effect is the strongest contributing factor to the cost savings.

Implementing single-use devices with a small footprint and eliminating steps strongly contributes to higher overall process yield. Figure 8 shows how the improved DSP recovery for scenario 3 directly translates into a 12% increase in the annual plant capacity and number of doses available for sale. This is the primary reason why process simplification and intensification are crucial for biopharmaceutical manufacturers and their patients.




Figure 8: Process intensification results in higher yearly plant output

Sensitivity analysis of process parameters

Selected input parameters were varied to study their effect on the total COGS. The load of the AEX step proved to have limited impact on the total process cost. Figure 9 shows a broad range of loadings between 50-400 g/L for the resin based AEX column and 2.5-20 kg/m² for Polisher ST membrane adsorber. For different loading levels, the required number of production capsules (pieces, pc) or resin volume after packing is shown. A single production capsule of Polisher ST membrane adsorber can process the batch from a 2000 L bioreactor for loadings between 5-20 kg/m². At 2.5 kg/m² loading (1/4 of the typical target loading), two capsules are needed, but this increases the total cost by only 2%.

At high impurity loads, it is more economical to use two capsules of Polisher ST membrane adsorber (COGS: 56.3 \$/g) than it is to combine a depth filter and Polisher ST membrane adsorber at the normal loading (COGS: 58.7 \$/g). At loads of 20 kg/m² or more, it becomes more economical to switch to the smaller BC2300 capsules of Polisher ST membrane adsorber.




Figure 9: Effect of AEX step load on total cost of goods

In scenario 1, the lifetime of the AEX resin was set to 150 Cycles. When this number was varied between 50 and 300, this resulted in less than 1% change in the total cost, as shown in Figure 10. If the AEX resin is used for less than 10 cycles, the cost increases strongly. The COGS for scenario 2, using the membrane adsorber, varied between 60.36 \$/G when used for 100 Cycles to 65.24 \$/g when used only once. As expected, the membrane adsorber offers the largest benefits over the column when a low number of cycles is applied.

The manufacturing cost when using Polisher ST membrane adsorber once is 55.37 \$/g, which is more economical than using the other membrane adsorber for 100 cycles. Hypothetical reuse of Polisher ST membrane adsorber for 10 or 100 cycles would result in a less than 1% change in the total cost. Small consumable savings would be offset by increases in buffer and labor cost, which would drive the cost slightly up, rather than down. Even if elution and regeneration of Polisher ST membrane adsorber were possible, it would not make sense economically.




Figure 10: Effect of number of AEX cycles

As mentioned in the previous section, the total DSP recovery has the largest impact on the process economics. In Figure 11, a representative range of unit recovery of the AEX step is shown for the different technologies. Due to their smaller size, functionalized membrane capsules generally result in a higher product recovery than columns. Even at worst case conditions of 95% yield, Polisher ST membrane adsorber results in significant cost savings compared to the first scenario (9% savings instead of 13% at 99% recovery). With depth filters generally being required to protect the AEX column, the recovery across the filter will also impact the Overall yield and cost. In Figure 11, this effect is shown for a depth filter recovery of 90% versus 95%.

Sensitivity analysis of process parameters (continued)




Figure 11: AEX recovery is directly correlated to cost of goods

The post VIN filtration steps are not expensive and account for only 2% of the batch cost in scenario 1, but these additional steps inevitably result in some product loss. Figure 12 shows the cost each of the technologies would have with and without protective filtration steps in front of them. Resin-based columns and membrane adsorbers typically need those filtration steps to prevent fouling and plugging, while Polisher ST membrane adsorber can operate in turbid, non-pretreated conditions.

In case the AEX column is replaced by Polisher ST membrane adsorber without elimination of the depth filter and the membrane, the cost is reduced by 8%. When the filtration steps are removed, the cost is reduced by 13%. This means that most of the cost

savings are due to the transition of the AEX step to a SUT but eliminating filtration steps further reduces the cost significantly.

The cost of the reusable membrane adsorber is shown for one cycle (single use) and 100 cycles. It is equally cost effective to use the membrane adsorber just once without pre-filtration than it is to include protective filters that enable reusing the adsorber 100 times.

Thermo Scientific™ Polisher ST Membrane Adsorber, which is designed to be used without pre-filters, has the lowest cost of the three options. This data confirms that it is more cost effective to apply a true single use solution that can operate in the presence of turbidity than it is to have a membrane or column that can be reused.




Figure 12: Effect of elimination of filtration steps

Conclusion

Polisher ST membrane adsorber can replace a multi-use AEX chromatography column or reusable membrane adsorber in large scale processes due to its high capacity and high recommended loading of 10 kg/m² of mAb. It is an economically viable alternative to reusable AEX products and can even reduce the cost of goods. Polisher ST membrane adsorber performance in AEX polishing unit operations can provide process simplifications that decrease the size and number of process steps and, thus, improve the productivity of the process.

If only the AEX column is replaced by Polisher ST membrane adsorber, the cost for the presented models is reduced by 8%. When the number of process steps is reduced by eliminating a protective depth filter and membrane, the cost savings increase to 13%. Compared to a reusable membrane adsorber, Polisher ST membrane adsorber offers an 8% decrease in cost.

The post VIN filtration steps have a negligible consumable cost but can result in a significant loss of the precious mAb product. These filtration steps are critical to prevent fouling and pressure increases on reusable chromatography products. With Polisher ST membrane adsorber being designed for single use and operation in turbid conditions, those protective filtration steps are no longer required. Our models show that it is more cost effective to have a true single use capsule than it is to regenerate and reuse.

Product recovery is one of the most important parameters for improving the cost of goods. Due to its small size and the reduction of process steps, Polisher ST membrane adsorber increases the total DSP recovery. Lower product losses directly result in a higher annual plant capacity and more doses being produced.

Model	Overall yield	Annual capacity	Doses produced	PMI	COGS
Scenario 1 (column)	58 %	584.4 kg	1.9 million	4,842	63.66 \$/g
Scenario 2 (membrane)	61 %	609.0 kg	2.0 million	4,383	60.36 \$/g
Scenario 3 (Thermo Scientific™ Polisher ST Membrane Adsorber)	65 %	654.2 kg	2.2 million	4,070	55.37 \$/g
Scenario 3 benefits over scenario 1	+7 %	+12 %	+12 %	-16%	-13%
Scenario 3 benefits over scenario 2	+4 %	+7%	+7%	-7%	-8%

Table 5: Summary results of comparison between AEX column, membrane adsorber and Thermo Scientific™ Polisher ST Membrane Adsorber

References

1. "Quantitative economic evaluation of single use disposables in bioprocessing", Andrew Sinclair, Miriam Monge, Pharmaceutical Engineering, 22. 20-34., January 2002
2. "A Single-use Strategy to Enable Manufacturing of Affordable Biologics", Renaud Jacquemart, Melissa Vandersluis, Mochao Zhao, Karan Sukhija, Navneet Sidhu, Jim Stout, Computational and Structural Biotechnology Journal, 14., July 2016
3. "Improving Process Mass Intensity for Bio/Pharmaceutical Production", J. Zhang, March 2019, PharmTech.com, [https:// www.pharmtech.com/view/improving-process-mass-intensitybiopharmaceutical-production](https://www.pharmtech.com/view/improving-process-mass-intensitybiopharmaceutical-production)
4. "Using Process Mass Intensity to Guide Process Development and Design", A. Cote et al., Presentation at the 13th Annual Green Chemistry & Engineering Conference, College Park, MD, June 2009

Appendix

A. Scenario 1 process

Table 6: Scenario 1 - process sequence

No	Process stage	Unit op name	Conc (g/L)	Yield (%)	Duration (hr)	Adjusted duration (hr)	Mass in (g)	Mass out (g)	Vol in (L)	Vol out (L)	Target out	Capacity out (kg/year)
		Feed	0.0							16.0		
1	Upstream	N-2 seed	0.0	0%	184.5	61.5	0.0	0.0	16.0	80.0	0.0	0.0
2	Upstream	N-1 seed	0.0	0%	184.5	61.5	0.0	0.0	80.0	400.0	0.0	0.0
3	Upstream	Production	5.0	100%	390.5	65.1	0.0	10,000.0	400.0	2,000.0	10.0	1,000.0
4	Recovery	Primary depth filter	4.3	90%	2.0	2.0	10,000.0	9,000.0	2,000.0	2,112.0	9.0	900.0
5	Recovery	Secondary depth filter	3.9	95%	1.7	1.7	9,000.0	8,550.0	2,112.0	2,168.0	8.6	855.0
6	Purification	Filtration (0.2 µm)	3.8	98%	2.1	2.1	8,550.0	8,379.0	2,168.0	2,179.8	8.4	837.9
7	Purification	Protein A	15.1	90%	11.6	27.6	8,379.0	7,541.1	2,179.8	498.8	7.5	754.1
8	Purification	Virus inactivation	14.5	98%	4.5	4.5	7,541.1	7,390.3	498.8	508.8	7.4	739.0
9	Recovery	Depth filtration	13.6	95%	2.0	2.0	7,390.3	7,020.8	508.8	516.8	7.0	702.1
10	Purification	Filtration (0.2 µm)	13.2	98%	1.9	1.9	7,020.8	6,880.3	516.8	520.7	6.9	688.0
11	Purification	AIEX flow through	12.6	95%	4.6	4.6	6,880.3	6,536.3	520.7	520.7	6.5	653.6
12	Purification	IEX bind & elute	13.3	95%	8.7	8.7	6,536.3	6,209.5	520.7	467.6	6.2	621.0
13	Purification	Viral filtration	12.7	98%	3.0	3.0	6,209.5	6,085.3	467.6	477.6	6.1	608.5
14	Purification	UF/DF	50.0	98%	8.1	8.1	6,085.3	5,963.6	477.6	119.3	6.0	596.4
15	Purification	Filtration (0.2 µm)	47.4	98%	1.0	1.0	5,963.6	5,844.3	119.3	123.2	5.8	584.4

Table 7: Scenario 1 process - cost of goods breakdown (USD per batch)

	N-2 seed	N-1 seed	Production	Primary depth filter	Secondary depth filter	Filtration (0.2µm)	Protein A	Virus inactivation	Depth filtration	Filtration (0.2)	AIEX flow through	IEX bind & elute	Viral filtration	UF/DF	Filtration (0.2 µm)
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15
Equipment (total)	724,994	1,136,934	5,289,622	121,375	60,688	113,943	1,154,310	170,725	23,071	101,684	967,800	1,106,682	90,593	535,809	75,132
Capital	6,518	10,222	47,558	1,091	546	1,024	10,378	1,535	207	914	8,701	9,950	815	4,817	676
Materials	1,735	4,016	14,725	1,194	1,179	1,452	5,118	1,165	1,166	1,165	1,588	1,690	1,167	1,322	1,165
Consumables	4,412	5,306	16,664	17,898	7,917	1,169	32,377	2,963	1,131	464	9,037	8,602	21,960	3,658	1,464
Labour	2,869	3,211	18,283	1,088	864	3,334	9,673	2,764	877	839	5,555	9,332	1,304	4,534	418
Other	1,628	2,565	11,939	373	186	516	2,893	385	59	229	2,240	2,630	206	1,241	170
	5%	7%	29%	6%	3%	2%	16%	2%	1%	1%	7%	9%	7%	4%	1%
Perfusion factor	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
Capital charge	6,518	10,222	47,558	1,091	546	1,024	10,378	1,535	207	914	8,701	9,950	815	4,817	676
Materials	1,735	4,016	14,725	1,194	1,179	1,452	5,118	1,165	1,166	1,165	1,588	1,690	1,167	1,322	1,165
Media	570	2,852	13,560	0	0	0	0	0	0	0	0	0	0	0	0
Buffer	0	0	0	30	15	3	3,954	1	2	1	424	525	3	158	1
Direct RM	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Bought WFI & PW	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CIP	0	0	0	0	0	285	0	0	0	0	0	0	0	0	0
QC tests	1,164	1,164	1,164	1,164	1,164	1,164	1,164	1,164	1,164	1,164	1,164	1,164	1,164	1,164	1,164
Consumables	4,412	5,306	16,664	17,898	7,917	1,169	32,377	2,963	1,131	464	9,037	8,602	21,960	3,658	1,464
Resins/MA	0	0	0	0	0	0	26,959	0	0	0	1,088	3,006	0	0	0
Bags	4,412	5,306	16,664	2,064	0	0	4,477	2,963	0	0	7,949	5,596	1,160	1,000	1,000
Filters	0	0	0	15,834	7,917	1,169	941	0	1,131	464	0	0	20,800	2,658	464
Packages	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Labour	2,869	3,211	18,283	1,088	864	3,334	9,673	2,764	877	839	5,555	9,332	1,304	4,534	418
Process	1,205	1,349	7,680	457	363	1,401	4,064	1,161	368	353	2,334	3,920	548	1,905	176
Quality	1,206	1,350	7,684	457	363	1,401	4,066	1,162	369	353	2,335	3,922	548	1,906	176
Indirect	458	513	2,919	174	138	532	1,544	441	140	134	887	1,490	208	724	67
Other	1,628	2,565	11,939	373	186	516	2,893	385	59	229	2,240	2,630	206	1,241	170
Insurance/other	338	530	2,467	57	28	53	538	80	11	47	451	516	42	250	35
Waste mgmt	0.99	1.53	5.53	32.71	15.33	1.78	5.82	2.19	2.19	0.29	7.23	5.12	1.98	0.87	0.71
Maintenance	306	481	2,236	51	26	48	488	72	10	43	409	468	38	226	32
Utilities	983	1,553	7,230	233	116	413	1,861	231	36	139	1,372	1,641	124	764	103
TOTAL (USD)	17,162	25,321	109,169	21,645	10,691	7,496	60,440	8,812	3,440	3,612	27,122	32,204	25,452	15,573	3,893
Total (USD/gram normalized for the output)	2.9	4.3	18.7	3.7	1.8	1.3	10.3	1.5	0.6	0.6	4.6	5.5	4.4	2.7	0.7

Appendix (continued)

A. Scenario 2 process

Table 8: Scenario 2 - process sequence

No	Process stage	Unit op name	Conc (g/L)	Yield (%)	Duration (hr)	Adjusted duration (hr)	Mass in (g)	Mass out (g)	Vol in (L)	Vol out (L)	Target out	Capacity out (kg/year)
		Feed	0.0							16.0		
1	Upstream	N-2 seed	0.0	0%	184.5	61.5	0.0	0.0	16.0	80.0	0.0	0.0
2	Upstream	N-1 seed	0.0	0%	184.5	61.5	0.0	0.0	80.0	400.0	0.0	0.0
3	Upstream	Production	5.0	100%	390.5	65.1	0.0	10,000.0	400.0	2,000.0	10.0	1,000.0
4	Recovery	Primary depth filter	4.3	90%	2.0	2.0	10,000.0	9,000.0	2,000.0	2,112.0	9.0	900.0
5	Recovery	Secondary depth filter	3.9	95%	1.7	1.7	9,000.0	8,550.0	2,112.0	2,168.0	8.6	855.0
6	Recovery	Filtration (0.2 µm)	3.8	98%	2.1	2.1	8,550.0	8,379.0	2,168.0	2,179.8	8.4	837.9
7	Purification	Protein A	15.1	90%	11.6	27.6	8,379.0	7,541.1	2,179.8	498.8	7.5	754.1
8	Purification	Virus inactivation	14.5	98%	4.5	4.5	7,541.1	7,390.3	498.8	508.8	7.4	739.0
9	Purification	Depth filtration	13.6	95%	2.0	2.0	7,390.3	7,020.8	508.8	516.8	7.0	702.1
10	Purification	Filtration (0.2 µm)	13.2	98%	2.2	2.2	7,020.8	6,880.3	516.8	520.7	6.9	688.0
11	Purification	Membrane adsorber	12.5	99%	0.8	0.8	6,880.3	6,811.5	520.7	545.7	6.8	681.2
12	Purification	IEX bind & elute	13.8	95%	8.8	8.8	6,811.5	6,471.0	545.7	467.6	6.5	647.1
13	Purification	Viral filtration	13.3	98%	3.0	3.0	6,471.0	6,341.5	467.6	477.6	6.3	634.2
14	Purification	UF/DF	50.0	98%	8.2	8.2	6,341.5	6,214.7	477.6	124.3	6.2	621.5
15	Purification	Filtration (0.2 µm)	47.5	98%	1.0	1.0	6,214.7	6,090.4	124.3	128.2	6.1	609.0

Table 9: Scenario 2 process - cost of goods breakdown (USD per batch)

	N-2 seed	N-1 seed	Production	Primary depth filter	Secondary depth filter	Filtration (0.2 µm)	Protein A	Virus inactivation	Depth filtration	Filtration (0.2 µm)	Membrane adsorber	IEX bind & elute	Viral filtration	UF/DF	Filtration (0.2 µm)
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15
Equipment (total)	728,849	1,142,980	5,317,751	124,079	62,039	114,765	1,177,440	175,566	23,340	102,296	696,851	1,166,491	91,259	551,873	75,603
Capital	6,562	10,291	47,878	1,117	559	1,033	10,601	1,581	210	921	6,274	10,502	822	4,969	681
Materials	1,735	4,016	14,725	1,194	1,179	1,452	5,118	1,165	1,166	1,165	1,205	1,690	1,167	1,329	1,165
Consumables	4,412	5,306	16,664	17,898	7,917	1,169	32,377	3,152	1,131	464	3,201	11,461	21,960	3,658	1,464
Labour	2,949	3,301	18,794	1,111	884	3,426	9,943	2,156	901	990	3,818	10,189	1,340	4,707	436
Other	1,639	2,582	12,019	380	189	518	2,949	397	59	231	1,571	2,770	208	1,280	172
	5%	7%	30%	6%	3%	2%	17%	2%	1%	1%	4%	10%	7%	4%	1%
Perfusion factor	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
Capital charge	6,562	10,291	47,878	1,117	559	1,033	10,601	1,581	210	921	6,274	10,502	822	4,969	681
Materials	1,735	4,016	14,725	1,194	1,179	1,452	5,118	1,165	1,166	1,165	1,205	1,690	1,167	1,329	1,165
Media	570	2,852	13,560	0	0	0	0	0	0	0	0	0	0	0	0
Buffer	0	0	0	30	15	3	3,954	1	2	1	40	525	3	165	1
Direct RM	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Bought WFI & PW	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CIP	0	0	0	0	0	285	0	0	0	0	0	0	0	0	0
QC tests	1,164	1,164	1,164	1,164	1,164	1,164	1,164	1,164	1,164	1,164	1,164	1,164	1,164	1,164	1,164
Consumables	4,412	5,306	16,664	17,898	7,917	1,169	32,377	3,152	1,131	464	3,201	11,461	21,960	3,658	1,464
Resins/MA	0	0	0	0	0	0	26,959	0	0	0	300	3,006	0	0	0
Bags	4,412	5,306	16,664	2,064	0	0	4,477	3,152	0	0	2,901	8,455	1,160	1,000	1,000
Filters	0	0	0	15,834	7,917	1,169	941	0	1,131	464	0	0	20,800	2,658	464
Packages	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Labour	2,949	3,301	18,794	1,111	884	3,426	9,943	2,156	901	990	3,818	10,189	1,340	4,707	436
Process	1,239	1,387	7,895	467	371	1,439	4,177	906	378	416	1,604	4,280	563	1,977	183
Quality	1,239	1,387	7,899	467	372	1,440	4,179	906	379	416	1,605	4,282	563	1,978	183
Indirect	471	527	3,000	177	141	547	1,587	344	144	158	609	1,627	214	751	70
Other	1,639	2,582	12,019	380	189	518	2,949	397	59	231	1,571	2,770	208	1,280	172
Insurance/other	341	534	2,485	58	29	54	550	82	11	48	326	545	43	258	35
Waste mgmt	0.99	1.53	5.53	32.71	15.33	1.78	5.82	2.19	2.19	0.29	1.71	7.40	1.98	0.88	0.71
Maintenance	308	484	2,251	53	26	49	498	74	10	43	295	494	39	234	32
Utilities	989	1,563	7,278	236	118	414	1,895	238	36	140	948	1,724	125	788	104
TOTAL (USD)	17,297	25,496	110,079	21,700	10,728	7,599	60,989	8,451	3,468	3,772	16,068	36,613	25,496	15,943	3,918
Total (USD/gram normalized for the output)	6,562	10,291	47,878	1,117	559	1,033	10,601	1,581	210	921	6,274	10,502	822	4,969	681

Appendix (continued)

C. Scenario 3 process

Table 10: Scenario 3 - Process sequence

No	Process stage	Unit op name	Conc (g/L)	Yield (%)	Duration (hr)	Adjusted duration (hr)	Mass in (g)	Mass out (g)	Vol in (L)	Vol out (L)	Target out	Capacity out (kg/year)
		Feed	0.0							16.0		
1	Upstream	N-2 seed	0.0	0%	184.5	61.5	0.0	0.0	16.0	80.0	0.0	0.0
2	Upstream	N-1 seed	0.0	0%	184.5	61.5	0.0	0.0	80.0	400.0	0.0	0.0
3	Upstream	Production	5.0	100%	390.5	65.1	0.0	10,000.0	400.0	2,000.0	10.0	1,000.0
4	Recovery	Primary depth filter	4.3	90%	2.0	2.0	10,000.0	9,000.0	2,000.0	2,112.0	9.0	900.0
5	Recovery	Secondary depth filter	3.9	95%	1.7	1.7	9,000.0	8,550.0	2,112.0	2,168.0	8.6	855.0
6	Purification	Filtration (0.2 µm)	3.8	98%	2.1	2.1	8,550.0	8,379.0	2,168.0	2,179.8	8.4	837.9
7	Purification	Protein A	15.1	90%	11.6	27.6	8,379.0	7,541.1	2,179.8	498.8	7.5	754.1
8	Purification	Virus inactivation	14.5	98%	4.5	4.5	7,541.1	7,390.3	498.8	508.8	7.4	739.0
9	Purification	Thermo Scientific™ Polisher ST Membrane Adsorber	13.2	99%	0.8	0.8	7,390.3	7,316.4	508.8	556.2	7.3	731.6
10	Purification	IEX bind & elute	14.9	95%	8.8	8.8	7,316.4	6,950.6	556.2	467.6	7.0	695.1
11	Purification	Viral filtration	14.3	98%	3.0	3.0	6,950.6	6,811.5	467.6	477.6	6.8	681.2
12	Purification	UF/DF	50.0	98%	8.3	8.3	6,811.5	6,675.3	477.6	133.5	6.7	667.5
13	Purification	Filtration (0.2 µm)	47.6	98%	0.9	0.9	6,675.3	6,541.8	133.5	137.4	6.5	654.2

Table 11: Scenario 3 - cost of goods breakdown (USD per batch)

	N-2 seed	N-1 seed	Production	Primary depth filter	Secondary depth filter	Filtration (0.2 µm)	Protein A	Virus inactivation	Thermo Scientific™ Polisher ST Membrane Adsorber	IEX bind & elute	Viral filtration	UF/DF	Filtration (0.2 µm)
	1	2	3	4	5	6	7	8	9	10	11	12	13
Equipment (total)	718,521	1,126,783	5,242,392	121,927	60,963	113,097	1,148,389	169,201	672,498	1,137,596	89,930	545,788	74,518
Capital	6,475	10,154	47,240	1,099	549	1,019	10,348	1,525	6,060	10,251	810	4,918	671
Materials	1,914	4,195	14,904	1,373	1,358	1,631	5,297	1,344	1,423	1,869	1,346	1,520	1,344
Consumables	4,412	5,306	16,664	17,898	7,917	1,169	32,377	2,963	6,753	11,461	21,960	3,658	1,464
Labour	2,947	3,299	18,781	1,101	879	3,423	9,937	2,839	1,407	10,187	1,338	4,805	412
Other	1,618	2,549	11,862	375	187	515	2,887	383	1,520	2,708	206	1,270	169
	5%	7%	30%	6%	3%	2%	17%	2%	5%	10%	7%	4%	1%
Perfusion factor	1	1	1	1	1	1	1	1	1	1	1	1	1
Capital charge	6,475	10,154	47,240	1,099	549	1,019	10,348	1,525	6,060	10,251	810	4,918	671
Materials	1,914	4,195	14,904	1,373	1,358	1,631	5,297	1,344	1,423	1,869	1,346	1,520	1,344
Media	570	2,852	13,560	0	0	0	0	0	0	0	0	0	0
Buffer	0	0	0	30	15	3	3,954	1	79	525	3	177	1
Direct RM	0	0	0	0	0	0	0	0	0	0	0	0	0
Bought WFI & PW	0	0	0	0	0	0	0	0	0	0	0	0	0
CIP	0	0	0	0	0	285	0	0	0	0	0	0	0
QC tests	1,343	1,343	1,343	1,343	1,343	1,343	1,343	1,343	1,343	1,343	1,343	1,343	1,343
Consumables	4,412	5,306	16,664	17,898	7,917	1,169	32,377	2,963	6,753	11,461	21,960	3,658	1,464
Resins/MA	0	0	0	0	0	0	26,959	0	5,500	3,006	0	0	0
Bags	4,412	5,306	16,664	2,064	0	0	4,477	2,963	1,253	8,455	1,160	1,000	1,000
Filters	0	0	0	15,834	7,917	1,169	941	0	0	0	20,800	2,658	464
Packages	0	0	0	0	0	0	0	0	0	0	0	0	0
Other	0	0	0	0	0	0	0	0	0	0	0	0	0
Labour	2,947	3,299	18,781	1,101	879	3,423	9,937	2,839	1,407	10,187	1,338	4,805	412
Process	1,226	1,373	7,816	458	366	1,425	4,136	1,182	585	4,240	557	2,000	171
Quality	1,254	1,404	7,995	469	374	1,457	4,230	1,209	599	4,336	570	2,045	175
Indirect	466	522	2,970	174	139	541	1,572	449	222	1,611	212	760	65
Other	1,618	2,549	11,862	375	187	515	2,887	383	1,520	2,708	206	1,270	169
Insurance/other	336	527	2,454	57	29	53	538	79	315	533	42	255	35
Waste mgmt	0.99	1.53	5.53	32.71	15.33	1.78	5.82	2.19	3.02	7.40	1.98	0.89	0.71
Maintenance	304	477	2,220	52	26	48	486	72	285	482	38	231	32
Utilities	976	1,542	7,182	234	117	412	1,857	230	918	1,686	123	783	102
TOTAL (USD)	17,365	25,502	109,451	21,846	10,890	7,757	60,846	9,054	17,163	36,476	25,660	16,171	4,061
Total (USD/gram normalized for the output)	2.7	3.9	16.7	3.3	1.7	1.2	9.3	1.4	2.6	5.6	3.9	2.5	0.6

Intended Use: Single-use filter products are intended for use in biopharmaceutical processing applications of aqueous based pharmaceuticals (drugs) and vaccines in accordance with the product instructions and specifications, and cGMP requirements, where applicable. Since there are many factors that can affect a product's use, the customer and user remain responsible for determining whether the Thermo Scientific product is suitable and appropriate for the user's specific application, including user conducting an appropriate risk assessment and evaluating the Thermo Scientific product in user's application.

Restrictions on Use: Thermo Fisher advises against the use of these Thermo Scientific products in any application other than the stated intended use(s), since other applications have not been evaluated by Thermo Fisher and may result in an unsafe or unintended condition. Do not use in any manner whereby the Thermo Scientific product, or any leachable from the Thermo Scientific product, may become part of or remains in a medical device that is regulated by any agency, and/or globally exemplary agencies, including but not limited to: a) FDA, b) European Medical Device Regulation (MDR), c) Japan Pharmaceuticals and Medical Devices Agency (PMDA) or in applications involving permanent implantation into the body; Life-sustaining medical applications; Applications requiring food contact compliance.

Technical Information: The technical information, guidance, and other statements contained in this document or otherwise provided by Thermo Fisher are based upon records, tests, or experience that Thermo Fisher believes to be reliable, but the accuracy, completeness, and representative nature of such information is not guaranteed. Such information is intended for people with knowledge and technical skills sufficient to assess and apply their own informed judgment to the information. No license under any Thermo Fisher or third-party intellectual property rights is granted or implied with this information.

Product Selection and Use: Many factors beyond Thermo Fisher's control and uniquely within user's knowledge and control can affect the use and performance of a Thermo Scientific product in a particular application. As a result, end-user is solely responsible for evaluating the product and determining whether it is appropriate and suitable for end-user's application. Failure to properly evaluate, select, and use a Thermo Scientific product and appropriate safety products, or to meet all applicable safety regulations, may result in injury, sickness, death, and/or harm to property.

 For more information, contact your Thermo Fisher Scientific sales representative or visit thermofisher.com/bioprocessfiltration

thermo scientific